NZ593361A - Dipeptidyl peptidase iv inhibitors - Google Patents
Dipeptidyl peptidase iv inhibitorsInfo
- Publication number
- NZ593361A NZ593361A NZ593361A NZ59336110A NZ593361A NZ 593361 A NZ593361 A NZ 593361A NZ 593361 A NZ593361 A NZ 593361A NZ 59336110 A NZ59336110 A NZ 59336110A NZ 593361 A NZ593361 A NZ 593361A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carbonitrile
- acetyl
- pyrrolidine
- methyl
- compounds
- Prior art date
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010012655 Diabetic complications Diseases 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- FGKUTYVILUEBFU-IGNZVWTISA-N (2s)-1-[2-[[(1r,5r)-1,3,8,8-tetramethyl-2,4-dioxo-3-azabicyclo[3.2.1]octan-5-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N([C@]12CC[C@@](C1(C)C)(C)C(=O)N(C2=O)C)CC(=O)N1CCC[C@H]1C#N FGKUTYVILUEBFU-IGNZVWTISA-N 0.000 abstract 1
- QXHZRZZNNBKEIO-PRHHBONVSA-N (2s,4r)-4-fluoro-1-[2-[[(1r,3s)-1,2,2-trimethyl-3-[(4-methylsulfonylphenyl)sulfonylmethyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C([C@](CC1)(C)NCC(=O)N1[C@@H](C[C@@H](F)C1)C#N)(C)C)S(=O)(=O)C1=CC=C(S(C)(=O)=O)C=C1 QXHZRZZNNBKEIO-PRHHBONVSA-N 0.000 abstract 1
- ZFZVCKOOHHUNHE-LDDOYCOJSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-1,2,2-trimethyl-3-(1,2,4-triazol-1-ylmethyl)cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C([C@](CC1)(C)NCC(=O)N1[C@@H](C[C@H](F)C1)C#N)(C)C)N1C=NC=N1 ZFZVCKOOHHUNHE-LDDOYCOJSA-N 0.000 abstract 1
- ACFHUTXXVCLLDP-PCPGWFQFSA-N (2s,4s)-4-fluoro-1-[2-[[(1r,3s)-1,2,2-trimethyl-3-[[[5-(trifluoromethyl)pyridin-2-yl]amino]methyl]cyclopentyl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C([C@@H]1C([C@](CC1)(C)NCC(=O)N1[C@@H](C[C@H](F)C1)C#N)(C)C)NC1=CC=C(C(F)(F)F)C=N1 ACFHUTXXVCLLDP-PCPGWFQFSA-N 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010056997 Impaired fasting glucose Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/08—Preparation by ring-closure
- C07D213/09—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles
- C07D213/12—Preparation by ring-closure involving the use of ammonia, amines, amine salts, or nitriles from unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN65CH2009 | 2009-01-09 | ||
| PCT/IB2010/000008 WO2010079413A2 (en) | 2009-01-09 | 2010-01-07 | Dipeptidyl peptidase iv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ593361A true NZ593361A (en) | 2012-12-21 |
Family
ID=42316906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ593361A NZ593361A (en) | 2009-01-09 | 2010-01-07 | Dipeptidyl peptidase iv inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8466145B2 (enExample) |
| EP (1) | EP2376447B1 (enExample) |
| JP (2) | JP2012514630A (enExample) |
| KR (1) | KR101750420B1 (enExample) |
| CN (2) | CN105384726A (enExample) |
| AU (1) | AU2010204144B2 (enExample) |
| BR (1) | BRPI1006970A2 (enExample) |
| CA (1) | CA2749301C (enExample) |
| ES (1) | ES2653563T3 (enExample) |
| HU (1) | HUE035693T2 (enExample) |
| IL (1) | IL213105A (enExample) |
| MX (1) | MX2011007340A (enExample) |
| NZ (1) | NZ593361A (enExample) |
| PL (1) | PL2376447T3 (enExample) |
| PT (1) | PT2376447T (enExample) |
| SG (1) | SG172924A1 (enExample) |
| WO (1) | WO2010079413A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101750420B1 (ko) * | 2009-01-09 | 2017-06-26 | 오키드 파마 리미티드 | 디펩티딜 펩티다제 ｉｖ 억제제 |
| CN103787960A (zh) * | 2014-02-27 | 2014-05-14 | 江苏省激素研究所股份有限公司 | 一种2-氯-5-三氯甲基吡啶的合成方法 |
| CN104496876A (zh) * | 2015-01-13 | 2015-04-08 | 佛山市赛维斯医药科技有限公司 | 一种羟基金刚烷酰胺衍生物、其制备方法和用途 |
| CN105596333A (zh) * | 2016-02-02 | 2016-05-25 | 白强 | 一种防治糖尿病及其并发症的药物组合物及其应用 |
| CN108707143B (zh) * | 2018-06-26 | 2020-06-26 | 中昱医学检验(广州)有限公司 | 一种dpp-4抑制剂及其制备和在糖尿病中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1567902A (en) * | 1975-10-15 | 1980-05-21 | Glaxo Lab Ltd | 1-aminoalkyl-7,7-dimethylnorbornanes |
| DE2659052A1 (de) * | 1976-12-27 | 1978-07-06 | Nattermann A & Cie | N-substituierte 1,2,2-trimethyl-3- carbamoyl-cyclopentan-carbonsaeuren(1) und deren physiologisch vertraegliche salze |
| DE3402623A1 (de) * | 1984-01-26 | 1985-08-01 | Bayer Ag, 5090 Leverkusen | Neue diisocyanate und ihre verwendung zur herstellung von polyurethankunststoffen |
| IT1201489B (it) | 1985-11-13 | 1989-02-02 | Chiesi Farma Spa | Derivati di tiazolidina,loro procedimento di preparazione e formulazioni farmaceutiche |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6482849B1 (en) | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
| TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| WO2003002553A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| AU2003225916A1 (en) | 2002-03-25 | 2003-10-13 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1589969A4 (en) | 2003-01-17 | 2008-08-13 | Merck & Co Inc | 3-AMINO-4-PHENYLBUTANEAN DERIVATEALS DIPEPTIDYLPEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| TW200519105A (en) * | 2003-10-20 | 2005-06-16 | Lg Life Science Ltd | Novel inhibitors of DPP-IV, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| WO2005075426A1 (en) | 2004-02-03 | 2005-08-18 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| CN101684089A (zh) * | 2004-02-05 | 2010-03-31 | 杏林制药株式会社 | 双环酯类衍生物 |
| BRPI0507905A (pt) | 2004-02-20 | 2007-07-10 | Novartis Ag | uso de compostos orgánicos |
| WO2005095339A1 (en) | 2004-03-31 | 2005-10-13 | Pfizer Products Inc. | Dicyanopyrrolidines as dipeptidyl peptidase iv inhibitors |
| WO2006012441A1 (en) * | 2004-07-23 | 2006-02-02 | Susan Marie Royalty | Peptidase inhibitors |
| JP2008507541A (ja) * | 2004-07-23 | 2008-03-13 | ロイヤルティ，スーザン・マリー | ペプチダーゼ阻害剤 |
| WO2006011035A1 (en) | 2004-07-23 | 2006-02-02 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them |
| AP2007003973A0 (en) * | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
| AU2007232311B2 (en) | 2006-04-03 | 2012-08-09 | Mylan Laboratories Ltd | Novel dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them |
| JP2009190971A (ja) * | 2006-06-06 | 2009-08-27 | Mitsubishi Tanabe Pharma Corp | ２−シアノピロリジン誘導体 |
| WO2008001195A2 (en) * | 2006-06-27 | 2008-01-03 | Glenmark Pharmaceuticals S.A. | Novel processes for the preparation of dpp iv inhibitors |
| JPWO2008114857A1 (ja) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
| KR101750420B1 (ko) * | 2009-01-09 | 2017-06-26 | 오키드 파마 리미티드 | 디펩티딜 펩티다제 ｉｖ 억제제 |
-
2010
- 2010-01-07 KR KR1020117016632A patent/KR101750420B1/ko not_active Expired - Fee Related
- 2010-01-07 NZ NZ593361A patent/NZ593361A/xx not_active IP Right Cessation
- 2010-01-07 EP EP10729125.4A patent/EP2376447B1/en not_active Not-in-force
- 2010-01-07 AU AU2010204144A patent/AU2010204144B2/en not_active Ceased
- 2010-01-07 CN CN201510549976.9A patent/CN105384726A/zh active Pending
- 2010-01-07 CA CA2749301A patent/CA2749301C/en not_active Expired - Fee Related
- 2010-01-07 US US13/140,997 patent/US8466145B2/en not_active Expired - Fee Related
- 2010-01-07 JP JP2011544937A patent/JP2012514630A/ja not_active Withdrawn
- 2010-01-07 CN CN2010800038403A patent/CN102272099A/zh active Pending
- 2010-01-07 ES ES10729125.4T patent/ES2653563T3/es active Active
- 2010-01-07 SG SG2011050085A patent/SG172924A1/en unknown
- 2010-01-07 PT PT107291254T patent/PT2376447T/pt unknown
- 2010-01-07 HU HUE10729125A patent/HUE035693T2/hu unknown
- 2010-01-07 PL PL10729125T patent/PL2376447T3/pl unknown
- 2010-01-07 WO PCT/IB2010/000008 patent/WO2010079413A2/en not_active Ceased
- 2010-01-07 MX MX2011007340A patent/MX2011007340A/es active IP Right Grant
- 2010-01-07 BR BRPI1006970A patent/BRPI1006970A2/pt not_active Application Discontinuation
-
2011
- 2011-05-24 IL IL213105A patent/IL213105A/en not_active IP Right Cessation
-
2015
- 2015-02-10 JP JP2015024634A patent/JP5775235B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL213105A (en) | 2015-09-24 |
| BRPI1006970A2 (pt) | 2015-09-15 |
| CN102272099A (zh) | 2011-12-07 |
| AU2010204144A1 (en) | 2011-06-23 |
| EP2376447B1 (en) | 2017-08-09 |
| US20110257164A1 (en) | 2011-10-20 |
| EP2376447A2 (en) | 2011-10-19 |
| HUE035693T2 (hu) | 2018-05-28 |
| RU2011133213A (ru) | 2013-02-20 |
| KR20110105820A (ko) | 2011-09-27 |
| JP5775235B2 (ja) | 2015-09-09 |
| CA2749301A1 (en) | 2010-07-15 |
| WO2010079413A2 (en) | 2010-07-15 |
| PT2376447T (pt) | 2017-11-15 |
| US8466145B2 (en) | 2013-06-18 |
| MX2011007340A (es) | 2011-07-21 |
| ES2653563T3 (es) | 2018-02-07 |
| WO2010079413A3 (en) | 2010-12-02 |
| CN105384726A (zh) | 2016-03-09 |
| JP2012514630A (ja) | 2012-06-28 |
| JP2015091889A (ja) | 2015-05-14 |
| EP2376447A4 (en) | 2012-06-20 |
| AU2010204144B2 (en) | 2012-02-16 |
| PL2376447T3 (pl) | 2018-04-30 |
| IL213105A0 (en) | 2011-07-31 |
| CA2749301C (en) | 2019-06-11 |
| KR101750420B1 (ko) | 2017-06-26 |
| SG172924A1 (en) | 2011-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11072582B2 (en) | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | |
| RU2345067C2 (ru) | Ингибиторы дпп-iv | |
| TWI358409B (en) | Heteroaryl substituted piperidine derivatives | |
| NZ593361A (en) | Dipeptidyl peptidase iv inhibitors | |
| RU2004112770A (ru) | Производные имидазол-4-карбоксамида, их получение и применение для лечения ожирения | |
| TWI432429B (zh) | 新穎苯基吡咯衍生物 | |
| MX2007008331A (es) | Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones. | |
| AU2011350629B2 (en) | Heterocyclic compounds suitable for the treatment of Dyslipidemia | |
| JP2010508338A5 (enExample) | ||
| ZA200502218B (en) | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) | |
| RU2005139525A (ru) | N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы | |
| NZ597247A (en) | Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme | |
| JP2008525476A5 (enExample) | ||
| IL320810A (en) | Glucagon-like peptide 1 receptor agonists | |
| US11339150B2 (en) | Benzimidazole compounds as HDAC6 inhibitors | |
| JP2005538109A5 (enExample) | ||
| JP5331001B2 (ja) | Ｃｂ１受容体モジュレーターとしての１，５−ジフェニル−３−ピリジニルアミノ−１，５−ジヒドロピロリジン−２−オン | |
| EP1871374B1 (en) | 2,3 substituted pyrazine sulfonamides as inhibitors of crth2 | |
| US9273041B2 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| TW200944514A (en) | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents | |
| JP2007512346A5 (enExample) | ||
| RU2014133987A (ru) | Новые производные азетидина | |
| JP6430246B2 (ja) | 微小管重合阻害剤 | |
| ATE396997T1 (de) | Substituierte, bizyklische 8-pyrrolidino- benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| JPWO2020115500A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED, IN Effective date: 20130108 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 07 JAN 2017 BY PIPERS Effective date: 20131202 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2018 BY PIPERS Effective date: 20170117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2019 BY PIPERS Effective date: 20180104 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 JAN 2020 BY PIPERS Effective date: 20190614 |
|
| LAPS | Patent lapsed |